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Abstract
It remains a mystery why HIV-associated end-organ pathologies
persist in the era of combined antiretroviral therapy (ART). One
possible mechanism is the continued production of HIV-encoded
proteins in latently HIV-infected T cells and macrophages. The
proapoptotic protein HIV-Nef persists in the blood of ART-treated
patients within extracellular vesicles (EVs) and peripheral blood
mononuclear cells. Here we demonstrate that HIV-Nef is present in
cells and EVs isolated fromBAL of patients on ART.We hypothesize
that HIV-Nef persistence in the lung induces endothelial apoptosis
leading to endothelial dysfunction and further pulmonary vascular
pathologies. The presence ofHIV-Nef in patientswithHIV correlates
with the surface expression of the proapoptotic endothelial-
monocyte–activating polypeptide II (EMAPII), which was
implicated in progression of pulmonary emphysema viamechanisms
involving endothelial cell death. HIV-Nef protein induces EMAPII
surface expression in human embryonic kidney 293T cells, T cells,
andhumanandmouse lung endothelial cells.HIV-Nef packages itself
into EVs and increases the amount of EVs secreted from Nef-
expressing T cells and Nef-transfected human embryonic
kidney 293T cells. EVs from BAL of HIV1 patients and Nef-
transfected cells induce apoptosis in lung microvascular
endothelial cells by upregulating EMAPII surface expression in
a PAK2-dependent fashion. Transgenic expression of HIV-Nef
in vascular endothelial–cadherin1 endothelial cells leads to
lung rarefaction, characterized by reduced alveoli and overall
increase in lung inspiratory capacity. These changes occur
concomitantly with lung endothelial cell apoptosis. Together,
these data suggest that HIV-Nef induces endothelial cell
apoptosis via an EMAPII-dependent mechanism that is sufficient to
cause pulmonary vascular pathologies even in the absence of
inflammation.
Keywords: EMAPII; emphysema; endothelial; extracellular
vesicles; HIV-Nef
Clinical Relevance
This is the first report showing that the HIV virally encoded
protein Nef persists in the lungs of antiretroviral therapy–treated
patients with HIV even in the absence of viral replication. We
show that Nef persistence leads to endothelial cell apoptosis and
subsequent vascular damage and pulmonary pathologies.
Targeting Nef-induced endothelial damage using endothelial-
monocyte–activating polypeptide II–neutralizing antibody or
PAK2 inhibitors could be a viable therapeutic strategy to
combat HIV-induced pulmonary diseases.
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HIV-1 infection is poorly controlled by the
immune system and requires combined
antiretroviral therapy (ART) to avoid the
development of AIDS in the infected
population, which according to the Centers
for Disease Control and the World Health
Organization includes approximately 1.1
million people in the United States and 36.7
million worldwide. Although the effective
deployment of ART has dramatically
reduced the number of AIDS-related deaths,
individuals chronically infected with HIV
have an increased incidence of developing
several lung complications, including
emphysema, pulmonary hypertension,
and lung cancer (1–6). Interestingly,
development of emphysema often occurs at
an earlier age in patients with HIV (i.e., in
20–40 yr-old patients, compared with 50–
70 yr-old individuals without HIV),
independently of cigarette smoking status
(2, 3, 7). We have previously demonstrated
that excessive endothelial apoptosis and
inflammation, both of which significantly
contribute to the development of cigarette
smoke–induced emphysema in mice, are
linked to the release of a proinflammatory
cytokine, endothelial-monocyte–activating
polypeptide II (EMAPII) (8). EMAPII is an
intracellular protein that is transported to
the cell surface and released in response
to various stresses, including hypoxia,
mechanical strain, apoptosis, TNF-a,
cigarette smoke, and HIV envelope protein
(9–13). In the context of the HIV virus, we
have demonstrated that HIV-gp120 causes
concerted upregulation of EMAPII and
its CXCR3 receptor to induce apoptosis,
suggesting a novel autocrine/paracrine
mechanism of endothelial cell apoptosis in
HIV infection (13).
Although most HIV1 patients on
ART have undetectable viral loads, the
persistence of HIV viral proteins in
multiple cell populations could be
responsible for the higher incidence of
vascular diseases. We have shown the
presence of intracellular HIV-Nef protein
in peripheral blood mononuclear cells from
patients with HIV, including those on ART
(14). Importantly, we found HIV-Nef in
HIV-uninfected T cells and B cells, showing
for the first time that HIV-Nef protein is
able to transfer independently from cell to
cell. The most likely mechanism of HIV-
Nef transfer into circulating blood cells is
through extracellular vesicles (EVs), which
are transported in the blood plasma and
can circulate rapidly through cells. In fact,
several independent groups have identified
HIV-Nef proteins in EVs from the plasma
of HIV-infected patients, including those
on ART (15–21). In this study, we sought to
investigate whether HIV-Nef protein could
be found in the lungs of patients with HIV
on ART and thereby contribute to the
development of pulmonary vascular
diseases. We analyzed cells and acellular
fluid derived from BAL in HIV1 patients
on ART for a minimum of 3 years with
documented good viral control. Using flow
cytometry, ELISA, and Western blotting,
we stained for intracellular and extracellular
vesicular HIV-Nef, and identified several
patients who were positive for HIV-Nef
even though they had undetectable viral
loads. We further observed a strong
correlation between HIV-Nef protein
expression and EMAPII release, and
identified EMAPII as the key mediator of
HIV-Nef–induced vascular endothelial
apoptosis leading to pulmonary pathology
in both in vitro and in vivo models.
Methods
Tissue Culture
Human lung microvascular endothelial cells
(HMVECs) were obtained from Lonza
(CC2527) and cultured in microvascular
endothelial cell growth medium-2. SupT1
and Nef-estrogen receptor (Nef-ER)–
expressing SupT1 cells were obtained
from the AIDS Reagent Repository and
cultured in RPMI with 10% FBS. The
following reagents were obtained through
the National Institutes of Health AIDS
Reagent Program, Division of AIDS,
National Institute of Allergy and Infectious
Diseases: Nef-ER #31 clone from Drs. Scott
Walk, Kodi Ravichandran, and David
Rekosh; pcDNA3.1SF2Nef (catalog #11431)
from Dr. J. Victor Garcia; anti–HIV-1 SF2
Nef monoclonal (EH1) from Dr. James
Hoxie (catalog #2949); anti–HIV-1 Nef
polyclonal from Dr. Ronald Swanstrom;
and pNL4-3 from Dr. Malcolm Martin.
Jurkat T cells and human-derived peripheral
blood mononuclear cells (Indiana Blood
Center) were cultured in RPMI with 10%
FBS. Human embryonic kidney (HEK)
293T cells were cultured in Dulbecco’s
modified Eagle’s medium with 10% FBS.
Primary alveolar macrophages were
isolated from BAL fluid from healthy
volunteers and cultured in RPMI with
10% FBS.
EV Isolation and Characterization
EVs were isolated from acellular BAL fluid
and supernatant of control/Nef-expressing
cells by ultracentrifugation. The number
and size of the EVs released were assessed
using NanoSight.
FACS
FACS was performed as previously
described (22). Human-derived BAL cells
and mouse lung cells were fixed in 1%
paraformaldehyde for 15 min at room
temperature. Cells were stained for surface
markers for 45 min at room temperature,
permeabilized using the FoxP3 intracellular
staining kit (00-5523-00, eBioscience),
stained for intracellular proteins, and
acquired on a BD Fortessa cell analyzer.
Data were analyzed with FlowJo v10.
Detection of Secreted Cytokines
Cytokine levels in acellular BAL fluid
from patients with HIV and supernatants
of alveolar macrophages and HIV-
Nef–transfected HEK 293T cells were
measured using the BD Cytometric Bead
Array.
Apoptosis Detection
Apoptosis was measured in HMVECs using
Flexstation (Molecular Devices) by
detecting caspase 3 activity (APO Logix
Caspase 3/7, Cell Technology) and
mitochondrial depolarization (JC-1
Ab113850, Abcam). TUNEL staining was
performed using the Apo-BRDU apoptosis
detection kit (88-6671-88, Thermo Fisher)
and analyzed using flow cytometry.
Volume-related Stereology for
Calculation of the Total Number of
Alveoli
To induce HIV-Nef protein in endothelial
Nef transgenic (vascular endothelial [VE]-
cadherin-Nef) progeny, neither the mothers
nor the litters were given tetracycline. Lungs
were fixed with 4.5% paraformaldehyde,
volume was assessed by the water
displacement method, and alveoli were
quantified in 3-mm sections using
resorcin/fuchsin and Nuclear Fast Red
(Weigert’s elastin staining).
Physiological Assessment of Lungs in
Nef Transgenic Mice
Blood oxygenation levels were measured
in alert animals using a MouseOx Plus
neck sensor (Starr Life Sciences). Lung
inspiratory capacity was measured with the
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flexiVent system (Scireq) as previously
described (8).
BAL Samples
Acellular BAL fluid and cells derived from
BAL were obtained from HIV-11 patients
and non-HIV–infected patients, and from
the left lung of Nef transgenic mice.
Statistical Analysis
Samples were deidentified and the difference
between groups was analyzed using
Student’s t test with Welch’s correction,
one-way ANOVA with Tukey’s post hoc
multiple comparison, and Mann-Whitney
nonparametric tests as indicated. Spearman’s
nonparametric analysis was used
to determine correlation. Additional
information can be found in the data
supplement.
Results
HIV-Nef Protein Persists in the Lungs
of Patients with HIV on ART
To establish HIV-Nef protein persistence
and distribution in the lungs of patients with
HIV on ART, we analyzed cells and acellular
fluid from BAL obtained from patients
in a well-characterized cohort (Table 1).
We first stained BAL-derived cells for
intracellular HIV-Nef using three different
anti-Nef monoclonal antibodies directed
against three unique HIV-Nef epitopes
(EH1, 3D12, and SN20; Figure E1A in the
data supplement) to address the high
mutation rate of HIV proteins. We also
used a novel ultraviolet–nucleotide binding
site (UV-NBS) antibody labeling method
(Figures E1B and E1C) to enhance
sensitivity. In our patient cohort, we
detected HIV-Nef protein persistence in at
least 2% of BAL cells in nine out of 15
HIV1 patients on ART (Figures 1A and E2;
Table 1). Using markers for alveolar
macrophage and lymphocytes, we found
that HIV-Nef1 cells were distributed
throughout alveolar macrophages, CD4
T cells, and CD8 T cells (Figure 1B), which
is consistent with our previous finding that
HIV-Nef protein is widespread in blood
cells (14). In none of the examined samples
was the HIV virus detectable based on
staining for the HIV protein p24 (data not
shown) or deep sequencing for HIV viral
sequences (RNA and DNA) of BAL (data
not shown). In concert with recent findings
that HIV-Nef persists in plasma EVs of
ART patients (15), we demonstrated Nef
persistence in BAL-derived EVs (Figures 1C
and 1D; Table 1). We followed up on this
observation by studying the role of EVs in
the lung microenvironment of patients with
HIV. EVs isolated from BAL of three
randomly selected HIV1 and three HIV2
patients with matched smoking status were
evaluated for their effects on lung-derived
primary cells, i.e., HMVECs. Indeed, these
EVs from patients with HIV induced
apoptosis in HMVECs (Figure 1E).
These results highlight the fact that HIV-
Nef protein is widely distributed in the
lungs of patients with HIV even in the
absence of detectable HIV RNA,
and suggest that this persistence
corresponds to a detrimental effect in
patients’ lungs by promoting a proapoptotic
environment.
HIV-Nef Mediates Its Own Transfer
into EVs
HIV-Nef has been suggested to exert its
function through insertion into and
transport through EVs (17–21, 23, 24).
Here, we investigated how HIV-Nef
impacts EV formation and mediates its
own incorporation into EV. When HIV-
Nef was induced in a 4-hydro-tamoxifen
(4-HT)-inducible expression system using
a SupT1 T-cell cell line, a strong increase
in EV secretion was observed (Figure 2A).
Likewise, HIV-Nef transfection into HEK
293T cells resulted in an increase in the
number of secreted EVs (Figure 2B). This
HIV-Nef–induced increase in EV secretion
was abrogated when HEK 293T cells were
transfected with HIV-Nef F195R, a mutant
that is incapable of PAK2 activation (25,
26). This suggests that HIV-Nef modifies
EV packaging and secretion contingent
on PAK2 activation, a pathway that is
implicated in exocyst complex–mediated
vesicular transport and exocytosis.
Similarly, PAK2 inhibition with 5 mM
FRAX 597 reversed the HIV-Nef–induced
increase in EV release (Figures 2C and E3).
Interestingly, we found that PAK2
activation was also required for the
incorporation of HIV-Nef into EVs
(Figure 2D). HIV-Nef–containing EVs
from transfected cells and from patient
BAL samples induced the release of
proinflammatory cytokines such as TNF-a,
IL-6, MCP-1, IP-10, and RANTES
(regulated upon activation, normal T cell
expressed and secreted) (Figure 2E) when
added to freshly isolated primary human
alveolar macrophages. Our data suggest
that HIV-Nef persistence in the lung
involves packaging of HIV-Nef into EVs,
Table 1. Analysis of Cell and Acellular Fluid from Patient BAL
Patient
ID
Nef1 BAL
Cells (%)
[Nef] in BAL
Fluid–Derived
Extracellular
Vesicles
(ng/3 ml)
EMAPII1
BAL
Cells (%)
Antiretroviral
Therapy
Start Date
CD4
Cell
Counts
Smoking
Status
8 0.63 N/A 1.41 N/A HIV2 Yes
10 9.86 0 6.62 7/1/92 709 Former
16 3.13 0 6.06 6/15/11 707 Former
18 2.22 1.5 2.99 10/15/06 688 Former
19 6.75 6.5 12.3 N/A (HIV21) N/A Former
20 8.24 1.7 0.55 7/1/95 985 No
21 2.6 0 0.54 12/10/08 904 No
22 0.15 3.8 0.03 10/9/07 771 Yes
23 2.31 0 0.02 7/1/96 158 Yes
24 0.03 0 0.00 12/15/11 1305 Yes
25 2.83 8.5 3.23 7/1/08 495 No
26 0.27 6.5 0.12 6/15/10 737 Yes
27 0.5 N/A 0.1 N/A HIV2 Yes
28 18.4 4.7 0.25 7/1/10 966 No
29 0.2 0.5 0.06 7/1/96 158 Yes
30 0.21 4.3 0.1 5/1/13 231 Former
31 0.98 N/A 0 N/A HIV2 Yes
32 0.1 1.6 0.03 11/15/07 332 Former
Definition of abbreviation: EMAPII = endothelial-monocyte–activating polypeptide II; N/A = not available.
BAL fluid from 18 patients was analyzed for HIV-Nef persistence and EMAPII surface expression.
Antiretroviral therapy start date, CD4 cell counts, and the smoking status of each individual were also
characterized.
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and that these EVs are capable of
promoting pathological activities in vitro.
HIV-Nef Protein Induces EMAPII
Surface Expression
Based on our previous findings that the HIV
envelope protein GP120 induces the surface
expression and release of EMAPII, a central
mediator of emphysema development and
progression (10, 13, 27), we asked whether
the persistent intracellular HIV viral
protein HIV-Nef could also cause EMAPII
release.
First, we investigated whether cells
found in HIV-Nef–containing lung
microenvironments were enriched for
EMAPII surface expression. Indeed, we
observed a strong correlation between the
percentage of Nef1 cells in the BAL and the
percentage of EMAPII1 cells (Spearman’s
correlation coefficient, 0.74; P = 0.0006)
(Figure 3A).
To show that HIV-Nef expression can
independently induce EMAPII trafficking
to the cellular surface membrane, we
transfected HEK 293T cells with cDNA
to express HIV-Nef protein. Compared
with mock-transfected HEK 293T cells,
SF2 HIV-Nef–transfected cells showed
increased EMAPII surface expression
(P , 0.001) (Figure 3B). This EMAPII
upregulation was dependent on PAK2
activation, as the Nef F195R mutant did
not induce EMAPII surface expression
(Figure 3B). Likewise, addition of 5 mM
FRAX597, a PAK2 inhibitor, abrogated
EMAPII surface expression in HIV-
Nef–transfected HEK 293T cells (Figure
E4B). Similarly, 4-HT activation of Nef-
ER–expressing SupT1 T cells also induced
an increase in surface EMAPII expression
(Figure E4A).
Next, we analyzed the impact of HIV-
Nef protein persistence in the lung on
EMAPII surface expression in the lung
endothelium. We tested the hypothesis that
Nef-containing EVs or Nef-expressing
T cells can induce EMAPII expression in
HMVECs. The addition of Nef-ER–expressing
SupT1 cells (Figure 3C) and EVs from
HIV-Nef–transfected HEK 293T cells
(Figure 3D) significantly induced EMAPII
surface expression in HMVECs. Again, the
use of a PAK2 activation-incapable mutant
(Figure 3D) abrogated EMAPII surface
expression in EV-treated HMVECs and
pulmonary arterial endothelial cells
(Figure E4C).
Other investigators and we have
reported that HIV-Nef protein can be
transferred to endothelial cells and that
its transfer stresses endothelial cells, which
is a precursor for the development for
vascular lesions (28–30). Based on these
reports, we wanted to know whether
HIV-Nef in endothelial cells is sufficient
to cause EMAPII upregulation in vivo.
To this end, we crossed HIV-Nef
transgenic mice containing the tetracycline-
responsive element with the VE-cadherin
promoter–controlled tet-off-transactivator
mouse line (31). The resulting offspring
were kept for the duration of life without
tetracycline to induce endothelial HIV-Nef,
which led to a statistically significant rise in
EMAPII surface expressing endothelial cells
isolated from the lungs of VE-cadherin-Nef
double-transgenic versus wild-type (WT)
littermates (Figure 3E).
These data suggest that HIV-Nef
persistence in the ART-treated HIV
population leads to EMAPII upregulation
in vitro and in vivo.
HIV-Nef Protein Induces Lung
Endothelial Cell Apoptosis in an
EMAPII-Dependent Fashion
We have previously shown that HIV-Nef
protein can independently mediate its
transfer from T cells to endothelial cells.
We also found that HIV-Nef transfer
is necessary and sufficient to induce
endothelial cell reactive oxygen species
production and apoptosis (30). Here,
when we investigated the role of EMAPII
surface expression in HIV-induced
endothelial cell apoptosis, we observed a
significant increase in apoptosis of
HMVECs when they were cocultured with
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Figure 1. HIV-Nef protein persists in lungs of patients with HIV on antiretroviral therapy. (A) HIV-Nef
protein was detected intracellularly in BAL-derived cells using flow cytometry (% Nef1 cells). (B) BAL cells
from six patients were costained with cell subtype markers to characterize HIV-Nef protein–positive cells as
either CD4 T cells (blue triangles), CD8 T cells (green squares), or alveolar macrophages (black stars). (C)
HIV-Nef in extracellular vesicles (EVs) isolated from acellular BAL fluid (BALF) was quantified by ELISA
(ng/ml). (D) Western blot analysis of EVs isolated from acellular BALF (top: anti-Nef SN43ab; bottom: anti-
Nef polyclonal Rb serum). (E) Apoptosis in human lung microvascular endothelial cells (HMVECs) was
measured using caspase 3 activity upon addition of acellular BALF-derived EVs from three HIV2 and HIV1
patients (with matched smoking status). The mean of the two groups was compared using the Mann-
Whitney test.
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HIV-NL43–infected Jurkat T cells
(Figure 4A), which was abolished in cells
treated with anti-EMAPII antibodies. We
previously showed that HIV-induced
human coronary artery endothelial cell
apoptosis was HIV-Nef dependent (30).
Supporting this finding, HIV-induced
HMVEC apoptosis was also HIV-Nef
dependent. Jurkat cells infected with HIV-
NL4–3 mutant with defective Nef (NL4–3
DNef) had no significant upregulation
of HMVEC apoptosis compared with
uninfected Jurkat cells (Figure 4A).
To examine the role of EMAPII in
HIV-Nef–induced endothelial apoptosis,
we analyzed endothelial cell apoptosis in
the coculture model of Nef-ER–expressing
SupT1 cells (Nef-ER) and HMVECs.
Coincubation with 4-HT–activated Nef-ER
increased endothelial cell apoptosis as
measured by TUNEL staining (P , 0.05)
(Figure 4B) and promoted mitochondrial
depolarization, an early marker for
apoptosis as measured by JC-1 staining
(P , 0.01) (Figure 4C). The addition of
neutralizing antibodies against EMAPII and
the EMAPII receptor (CXCR3) abolished
Nef-ER cell–induced HMVEC apoptosis
(Figure 4B), and anti-EMAPII antibodies
prevented HMVEC mitochondrial
depolarization (Figure 4C), indicating that
EMAPII surface expression plays an
important role in mediating HIV-Nef–induced
endothelial apoptosis. Furthermore,
secreted EMAPII may potentiate
HIV-Nef–induced endothelial apoptosis,
as the addition of recombinant EMAPII
to a coculture of Nef-ER SupT1
T cells and endothelial cells further
enhanced endothelial cell apoptosis
(Figure E5).
Finally, when HIV-Nef1 and
HIV-Nef2 EVs (Figure 2B) were added
to endothelial cells, only the HIV-
Nef–containing EVs induced dose-
dependent (Figure E6A) apoptosis in
HMVECs after 24 hours, but not after
4 hours (Figure E6B). This HIV-Nef-
EV–induced apoptosis was prevented with
EMAPII-neutralizing antibody treatment
(Figure 4D). Taken together, these data
clearly demonstrate that HIV uses
HIV-Nef–induced and EMAP-mediated
pathways to induce apoptosis in endothelial
cells.
Endothelial HIV-Nef Expression in
Transgenic Mice Induces Pulmonary
Pathology
To test whether Nef transfer to the
endothelium is sufficient to cause
pulmonary pathologies, we analyzed mice
in which Nef was specifically expressed in
the endothelium under control of the VE-
cadherin promoter. At the age of 4 months,
Nef-expressing mice did not manifest
significant changes in weight compared with
their Nef2 WT littermates (data not
shown). However, pulse oximetry showed a
statistically significant reduction in blood
oxygenation (P = 0.016) in VE-cadherin-
Nef double transgenics (Figure 5A).
Pulmonary function tests in 5-month-old
animals showed a significant increase in
inspiratory capacity as measured using a
deep inflation maneuver (gray bars) and
extrapolated from a pressure–volume loop
(red bars) (Figure 5C), indicating lung
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tissue rarefaction (32). Indeed, stereological
analysis demonstrated a decrease in alveoli
numbers in HIV-Nef transgenic animals
compared with their Nef2 WT littermates
(Figures 5B and E7). Importantly,
endothelial cells from lungs of Nef-
expressing mice manifested a higher
percentage of cleaved caspase 31 cells
(Figure 5D), suggesting a possible role of
Nef-induced apoptosis in alveolar loss.
However, we failed to observe significant
changes in the wet/dry lung ratio, white
blood cell count and only a trend towards
protein infiltration in the lungs (Figures
E8A–E8C). These data highlight the notion
that HIV-Nef causes EMAPII-mediated
endothelial apoptosis, followed by lung
tissue rarefaction, and are in line with our
previous findings in lungs of EMAPII
transgenic mice (8).
Discussion
In this study, we report for the first time that
the virally encoded HIV-Nef protein persists
in the lungs of patients with HIV on ART in
both cells and EVs, as determined using
three different techniques (flow cytometry,
ELISA, and Western blot). In addition to
Nef ’s persistence in the blood (16, 20), our
discovery highlights a likely mechanism for
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Figure 3. HIV-Nef protein induces endothelial-monocyte–activating polypeptide II (EMAPII) surface expression. (A) BAL-derived cells from 17 patients in
the INHALD (Investigating HIV Associated Lung Disease) cohort were stained for intracellular Nef and surface EMAPII. The percentage of Nef1 and
EMAPII1 cells was quantified by flow cytometry. (B) EMAPII surface expression was measured in HEK 293T transfected with empty vector (mock), WT Nef,
or a Nef mutant that is incapable of activating PAK2 (Nef F195R). (C) EMAPII surface expression in HMVECs 24 hours after the addition of tamoxifen (4-HT)
activated Nef-expressing SupT1 T cells (Nef-ER) or 4-HT–activated control SupT1 T cells (SupT1). (D) EMAPII surface expression in HMVECs 24 hours
after the addition of EVs isolated from either WT Nef (Nef) or Nef-mutant (Nef F195R) transfected HEK 293T supernatants. (E) EMAPII surface expression
was measured in CD452/CD3262/CD311 cells isolated from lungs of HIV-Nef transgenic mice and their littermates. The means of each group were
compared using Student’s t test or one-way ANOVA with Tukey’s post hoc comparison. ns = not significant; VE-CAD = vascular endothelial-cadherin.
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HIV-Nef–induced pulmonary vascular
pathologies.
We also observed that HIV-Nef protein
could be found in lung macrophages and
CD41 and CD81 T cells in addition to
BAL-derived EVs (33, 34). Our hypothesis
that HIV-Nef mediates its transfer through
EVs is in line with findings showing the
persistence of HIV-Nef in plasma (16, 20)
and our previous discovery that this protein
is present in HIV2 T cells and B cells in the
blood (35). Although we do not have any
viremic patients with HIV in our cohort,
Lee and colleagues (20) noted that Nef
persists in plasma EVs of both viremic and
aviremic patients with HIV. They also
showed that both groups have similar EV
profiles, as characterized by an increase in
EV quantity and changes in microRNA and
protein cargo compared with noninfected
individuals.
The detection of HIV-Nef protein in
patients on ART has the potential to act as a
biomarker for HIV reservoir activity and
explain the inability of ART to prevent
the development of HIV-associated
cardiopulmonary vascular diseases. Hence,
we used a strict validation approach
deploying three monoclonal antibodies
directed against three distinct epitopes
(SN20, 3D12, and EH1; see Figures 1A
and E1A) to combat the high mutation
rate of the HIV virus. We also conjugated
our anti-Nef antibodies using a novel
ultraviolet–nucleotide binding site
conjugation system to enhance the
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Figure 4. EMAPII mediates HIV and HIV-Nef–induced endothelial apoptosis. (A) Effect of HIV-NL4-3–infected Jurkat T cells on apoptosis as determined
by TUNEL. (B) Coculture of 4-HT–activated Nef-ER–expressing SupT1 T cells (with/without EMAPII and CXCR3 neutralizing antibodies), and
4-HT–activated control SupT1 T cells induced HMVEC apoptosis as measured by TUNEL staining. (C) Confirmation of apoptosis staining through TUNEL
by JC-1 staining, which is indicative for mitochondrial function. Note the decreased staining of JC-1 after exposure to 4-HT–activated Nef-ER SupT1 cells.
(D) Effects on HMVEC apoptosis (determined by staining for active caspase 3) after addition of HIV-Nef–containing EVs from HEK 293T cells transfected
with WT HIV-Nef plasmid or HIV-Nef F195R mutant. The groups were compared using one-way ANOVA with Tukey’s post hoc comparison. Tx =
treatment.
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sensitivity and specificity of HIV-Nef
detection. We used a similarly rigorous
approach in our discovery of HIV-Nef
protein persistence inside EV isolated from
BAL. We validated our findings from a
commercially available anti-Nef ELISA kit
that was previously used to detect HIV-Nef
in plasma EV (16) with Western blot using
two different monoclonal antibodies against
Nef.
HIV-Nef is known to have the ability
to interact with vesicular trafficking
proteins and regulate EV secretion (36).
Similarly to previous studies in plasma
(24), we could not distinguish between
microparticles and exosomes, and hence
decided to use the term “extracellular
vesicles.” To the best of our knowledge;
this is the first report to demonstrate
Nef in EVs isolated from HIV-infected
patients’ BAL fluid. These EVs could
originate from latently HIV-infected T cells
and macrophages from HIV reservoirs in
the lymphatic system, as Nef-containing
EVs were shown to be CD451 (16).
Another possible cellular source for Nef-
containing EVs is the liver, based on
microRNA and effector protein profiling
of Nef-containing EVs isolated from
plasma (21).
Interestingly, HIV-Nef persistence in
the lungs of patients with HIV corresponds
to an increased presence of proinflammatory
chemokines in the lung milieu (Table 1).
Although it was not significant given
the relatively small number of patients
analyzed, there was a trend toward higher
chemokine levels in the HIV-Nef1 group
versus the HIV2 control and HIV-Nef2
groups, which was especially remarkable
for IP-10. It would be interesting to
address in longitudinal studies the
relevance of these differences in the
context of chronic obstructive pulmonary
disease (COPD) development, given that
we have available pulmonary function test
data (forced expiratory volume in 1 second
and DLCO) and computed tomography
scans of the lung. It would be desirable
to test whether blood samples also reflect
the changes observed in the lung (BAL).
However, considering the dilution factor
of BAL, all of the chemokines except
for RANTES are found in much higher
concentrations in the lung compared
with the blood. Furthermore, the effects
of Nef are more pronounced in the lung
than in the blood compartment, indicating
that the observed changes in chemokines
and possibly other cytokines are restricted
to the lung.
The ability of HIV-Nef to alter the
chemokine profile of alveolar macrophages
is important. These changes contributing
to T cell dysfunction are believed to be
one of the major mechanisms leading to
consistent imbalance of the pulmonary
microbiome (37–39). This imbalance both
contributes to chronic inflammation in the
lung and acts as a potential source for
increasing the risk for lung cancer. Using
alveolar macrophages, we highlight the
ability of HIV-Nef–containing EVs to
promote an inflammatory phenotype in a
lung-specific lens. These findings reflect the
ability of HIV-Nef–containing EVs to
promote activation of blood-derived
monocytes and macrophages, a common
feature in HIV-associated end-organ
diseases, including neurocognitive disorders
and atherosclerosis (17, 20, 21, 24, 40,
41). However, the lung pathologies we
characterized in our endothelial-specific
Nef-expressing mice can be specifically
attributed to increased endothelial cell
apoptosis (Figure 5D). Because in this
model we focused on the endothelium
as the target tissue, the absence of
inflammation in the lungs of these mice is
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Figure 5. HIV-Nef expression in endothelial cells leads to emphysema-like lung tissue rarefaction
in transgenic mice. Transgenic mice expressing HIV-Nef in VE-CAD1 cells display lung tissue
rarefaction. (A) Oximetry showed reduced oxygenation in the blood of HIV-Nef transgenic mice.
(B) Stereological analysis revealed a corresponding reduction in alveoli numbers in VE-CAD-Nef–expressing
lungs compared with WT littermates. (C) Inspiratory capacity was quantified using a deep inflation maneuver
(gray bars) and extrapolated from the pressure–volume loop (red bars) using flexiVent data analysis. (D)
Cleaved caspase-3 staining in CD452/CD326/CD311 cells from lungs. The means were compared
using Student’s t test with Welch’s correction; n . 5.
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not surprising (Figure E8A). Further studies
including injections of Nef-containing EVs
and/or transgenic mouse studies with
Nef–expressing alveolar macrophages are
required to evaluate the entire spectrum
of immunological and pathological
consequences of HIV-Nef-EV uptake by
alveolar macrophages.
Our finding that the persistence of
HIV-Nef protein in latent infection is
relevant with regard to end-organ diseases
reflects previous findings in other viral
infections; for example, adenoviral protein
E1Awas shown to persist in latent infections
and to prime the lungs for the development
of COPD/emphysema (42). Similarly, the
risk of developing a pulmonary disease
like COPD is heightened in patients with
HIV on ART. Here, we show that the
persistence of HIV-Nef protein in end
organs such as the lung could induce
secretion of proapoptotic EVs and thus act
as a precursor for the development of
pulmonary pathologies. In our extensively
characterized cohort of patients with HIV
on ART (Figures 1 and 2; Tables 1 and E1),
we discovered a close correlation between
HIV-Nef and EMAPII in BAL cells. This
is in line with our previous demonstration
that cigarette smoke also induces
upregulation of EMAPII, thus leading to
endothelial apoptosis (8, 43). Our findings
showing that HIV-Nef can use an EMAPII-
mediated pathway to induce endothelial
cell apoptosis may help explain lung
pathologies in patients with HIV because
endothelial cell death has been suggested as
an important mechanism for inducing lung
emphysema in rodents (44–47) and
humans (48). HIV-Nef–induced cytotoxic
lymphocyte activation and lung capillary
endothelial cell apoptosis may explain the
increased incidence of emphysema in
HIV-infected patients (6). Our results
demonstrate that transgenic expression
of HIV-Nef in the endothelium causes
remodeling resembling emphysematous
changes (Figures 5B–5D) in the lungs of
these mice. This effect was mediated by a
HIV-Nef–induced induction of endothelial
apoptosis rather than inflammation, as we
did not observe a significant increase in
inflammatory immune cells in the BAL
(Figure E8A), edema (Figure E8B) and only
a trend for protein content (Figure E8C).
Hence, in this study we focused on the
contribution of endothelial cell apoptosis to
the development of pulmonary pathology.
This observation is consistent with previous
data showing that apoptosis of lung
endothelial cells driven by vascular
endothelial growth factor receptor inhibitors
is sufficient to cause emphysematous
changes (47).
Although we did observe an increase
in surface EMAPII expression in lung
endothelial cells of Nef transgenic mice
(Figure 3E), we only detected a slight,
nonsignificant trend toward an increase in
secreted EMAPII in the BAL (Figure E8D).
Previously, we have shown that EMAPII,
which is secreted from the lung epithelium,
induces an emphysema-like phenotype in
mice with both increased apoptosis and
inflammation in the lungs (8). It is possible
that endothelial cell–only expression of
Nef causes EMAPII surface expression
restricted to the lung endothelium and local
apoptosis, whereas released EMAPII by
proteases also contributes to inflammation.
In support of this, our in vitro transmigration
experiments showed no significant
increase in transmigration of human
monocytic cell line (THP-1) toward
HMVECs treated with Nef-EVs (data not
shown), whereas alveolar macrophages treated
with Nef-EVs secreted proinflammatory
cytokines (Figure 2E). Future studies
expressing HIV-Nef in other cell types,
including alveolar macrophages, can
examine whether HIV-Nef can also
upregulate EMAPII secretion that in
turn drives inflammation.
Targeting an HIV-induced
proapoptotic pathway in endothelial cells
via blocking EMAPII with neutralizing
antibodies may be sufficient to treat HIV-
associated pulmonary diseases. Our data
suggest that transfer of HIV-Nef to the
vascular endothelium can cause pulmonary
emphysema–like changes (Figure 5). HIV-
Nef has already been associated with
another pulmonary vascular disease:
pulmonary hypertension (28, 29). Here, we
show that BAL fluid–derived EVs contain
HIV-Nef, and that HIV-Nef–containing
EVs induce EMAPII surface expression
in primary human pulmonary artery
endothelial cells (Figure E4C). It is
possible that HIV-Nef–containing EVs
from the lung act as the initial insult
that results in the loss of endothelium
that is characteristic of pulmonary
arterial hypertension. Given the recent
proposition that endothelial cell apoptosis
may be a common denominator for the
development of both emphysema and
pulmonary arterial hypertension (49,
50), the mechanism suggested here
to explain how HIV contributes to
endothelial apoptosis should be of general
interest. In this regard, targeting PAK2
activation–dependent EMAPII pathways
could be of therapeutic interest in
combating HIV-associated pulmonary
vascular diseases. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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